A RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED TRIAL OF GUATTERIA GAUMERI MOTHER TINCTURE IN THE MANAGEMENT OF HYPERLIPIDEMIA
Aim: Guatteria gaumeri has antioxidant, anti-inflammatory, and anti-diabetic activities. In the present randomized double-blind placebo-controlled trial is the efficacy of guatteria gaumeri mother tincture in hyperlipidemia. Hyperlipidemia patients meeting the inclusion criteria were randomly assigned to the treatment and placebo.
Methods: 30 patients in the treatment group took guatteria gaumeri mother tincture; whereas the patients in the placebo group took placebo mother tincture for 12 weeks. The lipid profiles of the patients were evaluated at baseline, and after 6 and 12 weeks of the clinical trial.
Results: The final results showed that guatteria gaumeri mother tincture significantly p-value 0.05 and improved LDL, HDL, cholesterol, compared to the placebo group. The guatteria gaumeri showed an inhibitory effect on hepatic enzymes and possible liver toxicity. No serious side effect was reported for guatteria gaumeri mother tincture administration. Therefore, guatteria gaumeri mother tincture could be considered as a supplement for the treatment of dyslipidemia.
2. Sanchez Resendiz, J. and Lerdo de Tejada, A. (1982) Cholesterol lowering effect of Guutteria gaumeri. Journal of Ethnophnrmacology 6, 239-242.
3. Juarez, F. (1974) Efecto Anticolesterolknico y Litontrfptico de la Guutteria gaumeri. T&is depregrado para obtener el Titulo de Medico Veterinario Zootecnista. Facultad de Medicina Veterinaria, Universidad National Autkioma de Mexico.
4. Guyton C, Hall JE. Lipid metabolism. In: Guyton and Hall Textbook of Medical Physiology 12th ed. Elsevier Saunders; 2006:819-827.
5. Gotto A, Pownall H. Manual of lipid disorders: reducing the risk for coronary heart disease. 2nd ed. Baltimore, MD: Williams and Wilkins; 1999:19.
6. Stulc T, Ceška R, Gotto AM Jr. Statin Intolerance: The clinician’s perspective. Curr Atheroscler Rep 2015; 17:69.
7. Gotto A, Pownall H. Manual of lipid disorders: reducing the risk for coronary heart disease. 2nd ed. Baltimore, MD: Williams and Wilkins; 1999:16.
8. Rifai N, Warnick GR, Dominiczak MH, eds. Handbook of Lipoprotein Testing. Washington, DC: AACC Press; 1997:14-15.
9. Gotto A, Assmann G, Carmena R. The International Lipid Handbook for Clinical Practice. 2nd ed. New York, NY: International Lipid Information Bureau; 2000:218.
10. Liu ZL, Liu JP, Zhang AL, Wu Q, Ruan Y, Lewith G, et al. Chinese herbal medicines for hypercholesterolemia. Cochrane Database Syst Rev. 2011 ;(7):CD008305.
11. Grundy SM. HMG-CoA reductase inhibitors for treatment of hypercholesterolemia. N Engl J Med. 1988; 319:24-33.
12. Stein ED, Sprecher KS, Allenby RL, Tosiello E, Whalen SR. A new potent synthetic hmg co-a reductase inhibitor: effect of 0.2 mg daily in subjects with primary hypercholesterolemia. J Cardio Pharmacol Ther. 2016; 2(1):7-16.
13. Rodríguez-Páez L, Juárez-Sanchez M, Antúnez-Solís J, Baeza I, Wong C. Alpha-asarone inhibit HMG-CoA reductase, lowers serum LDL-cholesterol levels and reduces biliary CSI in hypercholesterolemic rats. Phytomed. 2003; 10(5):397-404.
14. Boericke W. New Manual of Homoeopathic Materia Medica with Repertory. 3rd ed. New Delhi: Jain Publisher; 2007.317.
15. Boger CM. Boenninghausen’s Characteristic Materia Medica and Repertory. Reprint Edition. New Delhi: Jain Publisher; 1997.21.
16. Ornish D. Statins and the soul of medicine. Am J Cardiol 2002; 89:1286-90.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.